End of 2nd round of med-chem for the analgesic compound - Lead Selected

We have just finished our second round of medicinal chemistry, for optimisation of our marine-derived analgesic compound for the treatment of chronic pain.

This round of molecular profile optimisation has enabled the selection of our Lead drug, from over 120 analogue candidates. This is an important milestone in our technology.